Drug candidates for inhibition of HIV-I replication can target Src family kinases (SFK), such as Hck, that interact with Nef protein of the virus. Compounds characterized by such inhibitory activity were identified via an assay for kinase activity of an SFK in a Nef:SFK complex. Illustrative of inhibitors identified using the kinase assay are various 2,3-diaminoquinaxolines and furo[2,3-d]pyrimidines. The inventive inhibitors were found to arrest HIV-I viral replication in vitro.
The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.
IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS
申请人:CAMP4 THERAPEUTICS CORPORATION
公开号:US20210254056A1
公开(公告)日:2021-08-19
The present invention provides methods and compositions for the evaluation, alteration and/or optimization of gene signaling. Methods and systems are also provided which exploit the information generated in the identification of new targets and non-canonical signaling pathways.
US8541415B2
申请人:——
公开号:US8541415B2
公开(公告)日:2013-09-24
[EN] TARGETING AN HIV-1 NEF-HOST CELL KINASE COMPLEX<br/>[FR] CIBLAGE D'UN COMPLEXE NEF DE VIH 1/KINASE DE CELLULE HÔTE
申请人:UNIV PITTSBURGH
公开号:WO2009139886A2
公开(公告)日:2009-11-19
Drug candidates for inhibition of HIV-I replication can target Src family kinases (SFK), such as Hck, that interact with Nef protein of the virus. Compounds characterized by such inhibitory activity were identified via an assay for kinase activity of an SFK in a Nef:SFK complex. Illustrative of inhibitors identified using the kinase assay are various 2,3- diaminoquinaxolines and furo[2,3-d]pyrimidines. The inventive inhibitors were found to arrest HIV-I viral replication in vitro.